<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160068</url>
  </required_header>
  <id_info>
    <org_study_id>8322</org_study_id>
    <nct_id>NCT01160068</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fed Condition</brief_title>
  <official_title>A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Metformin Hydrochloride 1000 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics, India) to be Compared With Glucophage® (Metformin Hydrochloride) 1000 mg Tablets (Bristol-Myers Squibb, USA) in 48 + (2 Standby) Healthy, Adult, Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single dose bioavailability of Metformin Hydrochloride 1000 mg tablets (Dr.
      Reddy's Laboratories Ltd., Generics, India) with Glucophage (Metformin Hydrochloride) 1000 mg
      tablets (Bristol-Myers Squibb, USA) in 48 + (2 standby) healthy, adult, human subjects under
      fed conditions.

      To monitor adverse events and to ensure the safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-period, two-sequence, single
      dose,crossover bioequivalence study with at least 07 days of washout period between each drug
      administration under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence on Cmax, AUC, Tmax,t1/2 parameters</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucophage 1000 mg tablets of Bristol-Myers Squibb</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin Tablets 1000 mg</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage Tablets 1000 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucophage</intervention_name>
    <description>Glucophage 1000 mg tablets of Bristol-Myers Squibb</description>
    <arm_group_label>Glucophage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who provided written informed consent.

          -  Subjects who were healthy within 18-45 years of age (inclusive) weighing at least 50
             kg.

          -  Subjects who were within ±10% of ideal body weight in relation to height according to
             Life Insurance Corporation of India height-weight chart for non-medical cases.

          -  Subjects with normal health as determined by medical history and physical examination
             performed within 15 days prior to the commencement of the study.

          -  Subjects with normal ECG, X-ray and vital signs.

          -  Availability of subject for the entire study period and willingness to adhere to
             protocol requirements as evidenced by written informed consent

          -  If subject is a female volunteer and

               -  is of child bearing potential practicing an acceptable method of birth control
                  for the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies, diaphragm, intrauterine device(IUD), or abstinence.

               -  is postmenopausal for at least 1 year.

               -  is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject)

        Exclusion Criteria:

          -  Subjects incapable of understanding the informed consent.

          -  Subjects with BP:≤90/60 or BP≥140/90.

          -  History of hypersensitivity or idiosyncratic reaction to Metformin or other
             Biguanides.

          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal,
             endocrine, immunologic, neurologic and haematologic function.

          -  Regular smoker who smokes more than ten cigarettes daily and has difficulty in
             abstaining from smoking for the duration of each study period.

          -  Subjects who has taken over the counter or prescribed medications, including any
             enzyme modifying drugs or any systemic medication within the past 30 days prior to
             start of clinical period.

          -  History of any psychiatric illness, which may impair the ability to provide written,
             informed consent.

          -  Subjects who have a history of alcohol or substance abuse within the last 5 years.

          -  Subjects with clinically significant abnormal values of laboratory parameters.

          -  Subjects who have participated in any other clinical investigation using experimental
             drug or had bled more than 350 mL in the past 3 months.

          -  Subjects who tested positive at screening for HIV, HbsAg or HCV

          -  Subjects with positive urine drug screen test for drugs of abuse.

          -  Any subject in whom Metformin is contraindicated for medical reasons.

          -  Subjects who have used any drugs or substances such as herbal preparations known to be
             strong inhibitors of CYP enzymes (formerly known as cytochrome P450 enzymes) within 14
             days prior to the first dose.

          -  Female volunteers demonstrating a positive pregnancy screen.

          -  Female volunteers who are currently breast-feeding.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mangesh Kulkarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vimta Labs Ltd.</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra pradesh</state>
        <zip>500051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>July 12, 2010</last_update_submitted>
  <last_update_submitted_qc>July 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Vice President-Generics</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

